Paper Details

  1. Home
  2. Paper Details

A Review of the Efficacy and Safety of Genvoya® (Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide) in the Management of HIV-1 Infection.

Author: AngioneSara A, CherianSibyl M, ÖzdenerAyşe Elif

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This review examines the efficacy and safety of Genvoya®, a single-tablet regimen for HIV-1 infection, comparing it to regimens containing tenofovir disoproxil fumerate (TDF). It explores the impact of Genvoya® on renal impairment, bone mineral density, metabolic effects, and other adverse events.
Paper Details　
Original Abstract of the Article :
This review evaluates the efficacy and safety of Genvoya® (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide [EVG/c/TAF/FTC]), a single-tablet regimen used for the management of HIV-1 infection. Phase II and III randomized clinical trials evaluate the efficacy and safety of EVG/c/TA...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1177/0897190017710519

データ提供：米国国立医学図書館（NLM）

Genvoya: A New Oasis in the Desert of HIV Treatment

The desert of HIV treatment has seen remarkable advancements in recent years, with new medications offering hope and improved quality of life for patients. This research evaluates the efficacy and safety of Genvoya®, a single-tablet regimen that combines elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (EVG/c/TAF/FTC) for the management of HIV-1 infection. The authors review data from phase II and III randomized clinical trials, comparing the effectiveness of Genvoya® to regimens containing tenofovir disoproxil fumerate (TDF) and exploring the potential renal, bone, and metabolic effects of the drug.

Genvoya: A Promising New Option in the HIV Treatment Landscape

The study highlights the promising efficacy and safety profile of Genvoya®, demonstrating its effectiveness in suppressing HIV-1 viral load and maintaining long-term viral suppression. The authors also emphasize the favorable metabolic effects of Genvoya® compared to TDF-containing regimens, reducing concerns about potential adverse effects on renal function, bone mineral density, and lipid metabolism.

A Camel's Perspective: The Importance of Personalized Treatment

The desert of HIV treatment is vast and complex, with each patient's needs and circumstances being unique. This research underscores the importance of individualized treatment approaches, selecting medications based on their efficacy, safety profile, and potential for long-term adherence.

Dr. Camel's Conclusion

The quest for effective and safe HIV treatment is an ongoing journey through a desert of complex medical challenges. Genvoya® represents a promising new oasis in this landscape, offering a well-tolerated and effective single-tablet regimen for the management of HIV-1 infection. By embracing innovation and tailoring treatment plans to individual needs, we can continue to improve the lives of those living with HIV.

Date :
  1. Date Completed 2018-08-30
  2. Date Revised 2022-03-30
Further Info :

Pubmed ID

28558493

DOI: Digital Object Identifier

10.1177/0897190017710519

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.